Haploidentical hematopoietic cell transplantation (HHCT) using CD34 selected grafts is complicated by slow engraftment and immune reconstitution. Engraftment and immune reconstitution might be improved using CD3/CD19-depleted grafts and reduced intensity conditioning (RIC). We report on 28 patients after HHCT with CD3/CD19-depleted grafts using RIC, which were prospectively evaluated for engraftment and immune reconstitution. Engraftment was rapid with full chimerism reached on day þ 15 after HHCT. T-cell reconstitution was delayed with a median of 205 CD3 þ cells/ll, 70 CD3 þ CD4 þ cells/ll and 66 CD3 þ CD8 þ cells/ll on day þ 100, respectively. A skewed T-cell receptor-Vb repertoire with oligoclonal T-cell expansions to day þ 100 and normalization after day þ 200 was observed. B-cell reconstitution was slow with a median of 100 CD19 þ CD20 þ cells/ll on day þ 150. Natural killer (NK) cell engraftment was fast reaching normal values on day þ 20. An increased natural cytotoxicity receptor and NKG2A, but decreased NKG2D and KIR expressions were observed on NK cells until day þ 100. We observed a positive impact of donor lymphocyte infusions on immune reconstitution. In conclusion, after HHCT, using CD3/CD19-depleted grafts and RIC, T-and B-cell reconstitution is delayed, whereas NK-cell reconstitution occurs early and fast.
Introduction
Haploidentical hematopoietic cell transplantation (HHCT) is a valuable treatment option for patients lacking human leukocyte antigen (HLA)-matched related or unrelated donors. Initially, attempts of HHCT were complicated by graft rejection, high incidence of graft-versus-host disease (GVHD) and delayed immune reconstitution, resulting in a high incidence of infections and treatment-related mortality. 1 Graft rejection and GVHD are mediated mainly by T cells. Thus, various approaches were evaluated to deplete the host and the recipient T cells. The Perugia group pioneered an approach of graft T-cell depletion by positive selection of CD34 þ stem cells combined with transplantation of a megadose of these cells (410x10 6 CD34 þ cells/kg body weight) to overcome the HLA barrier. 2 An intense conditioning regimen using total body irradiation, thiotepa, fludarabine and anti-thymocyte globulin was used to eliminate the recipient T cells. The strategy allowed successful HHCT with a low rate of GVHD and a promising event-free survival for patients transplanted in complete remission. 3 In our own experience of HHCT, by using such approach we observed a high toxicity of the conditioning regimen, high treatmentrelated mortality and slow engraftment, namely of platelets and delayed immune reconstitution. A delayed engraftment was observed particularly with CD34 doses o8 Â 10 6 cells/kg body weight. 4 New strategies of graft manipulation using immunomagnetic cell depletion aimed to improve engraftment, making HHCT feasible even after reduced intensity conditioning (RIC) and without megadoses of CD34 þ cells. 5 On the basis of the promising experiences gained at St Jude Children's Research Hospital, Memphis, TN, USA in the pediatric population 6 , a new regimen using graft CD3/CD19 depletion with anti-CD3-and anti-CD19-coated microbeads on a CliniMACS device (Miltenyi Biotec, Bergisch-Gladbach, Germany) was developed. CD3/CD19-depleted grafts not only contain CD34 þ stem cells, but also contain CD34-negative progenitors, natural killer (NK) cells, dendritic-and other graft-facilitating cells, 7 and enable HHCT after RIC.
T-and B-cell depletion were used to reduce the risk of GVHD and to prevent Epstein-Barr virus-related lymphoproliferative disease. In addition to chemotherapy, the anti-CD3 monoclonal antibody OKT-3 was used to deplete the remaining T cells from the donor and avoid graft rejection. In contrast to anti-thymocyte globulin, OKT-3 spares facilitating cells such as NK cells in the graft. Using CD3/CD19-depleted haploidentical grafts and RIC with fludarabine, thiotepa and melphalan, we observed sustained, and in comparison to CD34-selection, accelerated engraftment without a megadose of CD34 þ stem cells even in an elderly and heavily pretreated patient population. 5, 8 Immune reconstitution after this approach for HHCT has not been studied in detail. We therefore prospectively analyzed the immune reconstitution in 28 adult patients receiving HHCT after RIC using CD3/CD19-depleted grafts.
Patients and methods

Patients
Between 2004 and 2009, 28 consecutive patients (13 women and 15 men) received HHCT at our institution (Table 1) . A total of 24 patients have been enrolled in a prospective phase II study of HHCT using CD3/CD19-depleted grafts and RIC. ClinicalTrials.gov identifier: NCT00202917. The study protocol was approved by our local Institutional Review Board. All patients signed an informed consent. Patients aged 18 to 65 years with hematological malignancies and high-risk disease, insufficient response to chemotherapy or relapse after autologous or allogeneic hematopoietic cell transplantation (HCT) were eligible for HHCT. All patients had no suitable HLA-matched related or unrelated donor. At the time of transplant, patients were either in complete remission or in partial remission with not more than 10% marrow blasts. In total, four patients were treated off-protocol because of refractory disease. Their treatment followed the above mentioned study protocol, but fludarabine was substituted by clofarabine in the conditioning.
Donors, stem-cell mobilization, collection and CD3/CD19 depletion Donors were either siblings (n ¼ 10), mothers (n ¼ 2), children (n ¼ 10) nephew (n ¼ 1) or cousins (n ¼ 5) of the patients. Donors were assessed for HLA compatibility by high-resolution molecular typing methods. All donor-recipient pairs had Xtwo HLA mismatches. If available, a killer-cell-like-immunoglobulin (KIR)-mismatched donor was chosen (16 of 28 patients). Peripheral blood mononuclear cells were mobilized and CD3/CD19 depletion was performed as previously described 5 using the automated CliniMACS device (Miltenyi Biotec). 9 Conditioning regimen and transplantation RIC consisted of fludarabine (150-200 mg/m 2 ) day À8 to À4, thiotepa (10 mg/kg) day À3, melphalan (120 mg/m 2 ) day À2 to À1 and OKT-3 (5 mg/day) day À5 to þ 14. In four patients, fludarabine was substituted by clofarabine (150 mg/m 2 ) because of refractory disease. All patients received cryopreserved peripheral blood stem cells processed with CD3/CD19 depletion on day 0. No granulocyte colony-stimulating factor was given post HHCT. As post grafting immunosuppression, mycophenolate mofetil (15 mg/kg b.i.d.) was used if the T-cell content in the graft was X5 Â 10 4 CD3 þ cells/kg.
Monitoring of engraftment, chimerism, immune reconstitution and donor lymphocyte infusions
Hematopoietic donor cell chimerism was monitored in all patients using microsatellite markers as described. 10 Additionally, T-cell chimerism was evaluated using microsatellite markers and flow cytometry-based evaluation. 11 Chimerism was tested weekly up to day þ 100 and after that monthly and at the time points of evaluation of immune reconstitution (40, 100, 150, 250 and 400 ( ± 10) days post HCT). Engraftment and immune reconstitution were assessed by peripheral blood counts and flow cytometry. Engraftment was defined as the first day with an absolute neutrophile count consistently 4500 cells/ml. Platelet engraftment was defined as the first day with consistently 420 000 platelets/ml. Patients received additional donor lymphocyte infusions in case of relapse or progression of underlying disease. Peripheral blood mononuclear cells were freshly obtained from the donor and adjusted to a defined CD3 þ T-lymphocyte content ranging from 2 Â 10 4 to 4 Â 10 4 CD3 þ cells/kg and given after various time points after HHCT.
Flow cytometry
Analysis of the initial leukapheresis product and CD3/CD19-depleted grafts was performed using flow cytometry. After transplantation, immune reconstitution was monitored in peripheral blood by flow cytometry on day þ 40, þ 100, þ 150, þ 250 and þ 400 ( ± 10 days). Flow cytometry (FACScalibur, Becton Dickinson, Heidelberg, Germany) was performed using the monoclonal antibodies described below. Absolute cell counts of T-, B-and NK-cells were evaluated using the white blood cell count from a hematology cell analyzer (SYSMEX, Norderstedt, Germany) and the flow cytometrically assessed percentage of the respective cell population
T-and B-cells. For analysis of T-and B-cells, monoclonal
antibodies labeled with phycoerythrin (PE) and fluorescein isothiocyanate (FITC) (CD3-FITC, CD19-PE/CD20-FITC) were used (all antibodies were from Becton Dickinson). T-cell subsets were evaluated using CD3-FITC/CD8-PE, CD3-FITC/CD4-PE, CD4-PE/CD45RA/R0-FITC, CD3-FITC/anti-TCRab-PE and CD3-FITC/anti-TCRgd-PE.
Analysis of the T-cell receptor repertoire. T-cell receptorVb repertoire was studied by flow cytometry using TCR-Vb repertoire kit (IO Test Beta Mark, Beckman Coulter GmbH, Krefeld, Germany) at different points of time in the first year after transplantation.
12 This method enables quantitative study of a total of 24 Vb-chains, resulting in analysis of 70% of the Vb repertoire. The distribution of control TCR-Vb repertoires of 85 normal subjects was used as reference for a normal distribution of Vb expression.
Analysis of the NK cells and NK-cell receptors. NK cells
were evaluated by flow cytometry using CD3-FITC/CD56/ CD16-PE (Becton Dickinson) on day þ 30, þ 60 and þ 90 after transplantation. A panel including the most important inhibitory and activating receptors was used. We analyzed NKP30, NKP44, NKP46, NKG2D, CD158a/b/e, CD85j, NKG2A Table 1 Patients characteristics
Median age, years (range) 45 Engraftment, days to 4500 cells/ml ANC: 12 (range, 9-15) Median (range) 420 000 cells/ml PLT: 11 (range, 8-23)
Death due to infections 10
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANC, absolute neutrophil count; CML, chronic myelogenous leukemia; CR, complete remission; GVHD, graft-versushost disease; HCT, hematopoietic cell transplantation; IPS, idiopathic pneumonia syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PLT, platelet count; PR, partial remission.
Immune reconstitution after CD3/CD19 depleted HHCT B Federmann et al and CD161. For CD161 staining, a PerCP-labeled primary antibody DX9 and a biotine-linked secondary antibody (both antibodies from Becton Dickinson) were used.
Statistical analysis
The GraphPadPrism 4.0 biostatistical software (GraphPad Prism Inc., La Jolla, CA, USA) was used for statistical analysis. Student's t-test for independent variables (unpaired t-test) was used to compare the quantitative data. A P-value o0.05 was considered to indicate a statistically significant difference between two groups. Results are given in medians (range) unless otherwise indicated. Survival was analyzed using Kaplan-Meier estimates.
Results
Clinical outcome and infections
At time of HHCT, 18 patients were in complete remission and 10 in partial remission (Table 1) . Grafts contained 8.6 Â 10 6 CD34 þ (range, 4.3-18) cells/kg, 2.9 Â 10 4 CD3 þ (range, 1.9-9.2) cells/kg and 2.9 Â 10 7 CD56 þ cells/kg (range, 0.02-23). Engraftment was rapid with a median of 12 days (range, 9-15) to 4500 granulocytes/ml and 11 days (range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] to 420 000 platelets/ml, respectively. Nonrelapse mortality was 2/28 (7%) up to day þ 100 and 11/28 (39%) for the whole period. To date, 10 patients died because of infections (idiopathic pneumonia syndrome (n ¼ 1), bacterial pneumonia (n ¼ 2), viral pneumonia (n ¼ 3), toxoplasmosis (n ¼ 1), meningitis of unknown origin (n ¼ 2) and aspergillosis (n ¼ 1)) and one because of progressive multifocal leucencephalopathy. One patient suffered EpsteinBarr virus-related lymphoproliferative disease and was treated with rituximab and radiation. We observed eight patients with cytomegalovirus reactivation (18/28 at risk) and six patients with a HHV-6 reactivation but without clinical symptoms. In 15 patients, (54%) acute GVHD occurred (II1 n ¼ 13 and III1 n ¼ 2) and 5 patients (18%) developed chronic GVHD (limited n ¼ 2 and extensive n ¼ 3). We did not observe any relation between death due to infections and the occurrence of GVHD or the T-cell count in the graft. Currently, 9/28 (32%) patients are alive, and eight patients are in complete remission and one in partial remission resulting in a Kaplan-Meier estimate 1-year overall survival (OS) of 54% and 2-year OS of 31% with a median follow-up of 748 days (range, 611-1809). Eight patients relapsed.
Chimerism
Complete donor chimerism was reached in a median on day þ 15 (range 9-47). Full chimerism was documented before engraftment of neutrophils in 8 of 28 patients. In 21 of the 28 patients, T-cell chimerism was further analyzed. Complete donor T-cell chimerism was reached at a median of 40 days (range 13-160) after HHCT. Therefore, T-cell reconstitution observed after HHCT was predominantly driven by expansion of donor T cells.
Immune reconstitution T cells and T-cell subsets. T-cell reconstitution was delayed
with median of 205 (range 38-799) CD3 þ cells/ml on day þ 100 and 369 CD3 þ cells/ml (range, 41-1418) on day þ 400, respectively ( Figure 1a) . Evaluating T-cell subsets, the reconstitution was delayed with a median of 66 CD3 þ /CD8 þ (range 8-170) versus 70 CD3 þ /CD4 þ cells (range 12-301) on day þ 100 and 193 (range 19-980) versus 177 (32-379) cells/ml on day þ 400, but there was no significant difference between the two groups (P ¼ 0.87) (Figure 1b) . Furthermore, we analyzed memory T cells with CD4 þ /45RO þ and naïve T cells with CD4 þ /45RA. Figure 1c shows a delayed reconstitution of naïve T cell to day þ 250, whereas the memory T cells reconstituted faster with a median of 28 CD4 þ 45RA þ (range 0-152) versus 79 CD4 þ 45R0 þ cells/ml (range 14-310) on day 100 and 115 (range 21-2396) versus 205 (range 46-327) on day þ 400, respectively (P ¼ 0.01).
Analyzing the CD3 þ /TCR-ab þ and Àgd þ T cells, we found a low expression of gd-T cells in comparison with the normal distribution (Figure 1d ). The subset of TCR-ab-T cells reconstituted delayed with a median of 63 cells/ml on day þ 100 (range, 0-421) and 225 cells/ml on day þ 400 (range, 135-1342) (P ¼ 0.001).
TCR-Vb repertoire. The TCR-Vb repertoires of 15 patients before and at different dates in the first year after HHCT were evaluated by flow cytometry. We found distinct differences in regeneration of the TCR repertoires in individual patients. Some patients had an altered TCR repertoire already before transplantation with a restricted expression of single Vb-chains. TCR repertoire regeneration was heterogeneous and not all patients achieved a complete, diverse TCR repertoire during the study period. In seven patients, the repertoire was scarce and in five patients it remained skewed and was restricted to the end of study. In most of the patients, we observed a reduced TCR repertoire in the early phase after HHCT with underexpression of several Vb-chains and a normalization of the repertoire after day þ 200. An overexpression of single Vb-chains was observed at different time points and sometimes could be correlated with clinical events. 
NK-cell receptors
Activating and inhibitory receptors were analyzed in eight patients. An increased expression of activating natural cytotoxicity receptors over time was observed. NKP44 showed a low expression with median of 1.9% (range 9.7-34.4%) on day þ 60, in contrast to NKP30 with a median of 41.9% (range, 9.6-95.3%) and NKP46 with 92.5% (range, 68.9-98.5%). The activating receptor NKG2D was highly expressed early after transplantation with a median of 82.7% (range, 8.5-99.0%) on day þ 30 and decreased with time to a median of 64.4% (range, 7.0-88.5%) on day þ 60 and 56.5% (range, 23.9-93.3%) on day þ 90, respectively (see Table 2 ). Among the inhibitory receptors we found that the receptor NKG2A highly expressed on 69.2% (median, range 26.1-89.6%) of NK cells on day þ 30. In contrast, a low expression of the KIR-receptors with median of 7.6% (range, 1.2-16.2%) of cells expressing KIR2DL1, a median of 36.0% (range, 5.3-58.2%) cells expressing KIR2DL2 and a median of 16.8% (range, 14.6-44.1%) cells expressing KIR3DL1 on day þ 30 were observed. The KIRs showed a delayed reconstitution with alternating expression of low level up to day þ 90 (Table 3 ). The prediction of NK-cell alloreactivity was based on the 'KIR-ligand' model. 13 In total, 16 patients were transplanted with a positive KIR-mismatch (KIR-MM), but we did neither see an advantage in OS (Kaplan-Meier estimate 1-year OS of 38% with KIR-MM versus 75% (P ¼ 0.14) without KIR-MM) in the overall patient population nor in the patients with acute myeloid leukemia (n ¼ 21) (Kaplan-Meier estimate 1-year OS of 38% with KIR-MM versus 57% without KIR-MM, P ¼ 0.17).
Donor lymphocytes. Eight patients received CD3 þ
T lymphocytes as DLI (five because of relapse, one because of mixed chimerism and two patients as antigen-specific T cells because of virus reactivation) ranging from 1 Â 10 4 to 1 Â 10 7 cells/kg at varying time points after HHCT (day þ 0-100, n ¼ 4; day þ 100-200, n ¼ 3; day þ 200-300, n ¼ 6; day þ 300-600, n ¼ 4). Two patients developed acute GVHD after receipt of DLI. DLI induced an accelerated reconstitution of CD3 þ T cells with median of 230 (range, 82-284) versus 191 (range, 38-799) cells/ml on day þ 100 (P ¼ 0.54) (Figure 5a ). Evaluating T-cell subsets, DLI had an effect on the immune reconstitution of CD3 þ CD8 þ T cells (P ¼ 0.25) (Figure 5b ) and anti-TCR-ab (P ¼ 0.63)/gd-T cells (P ¼ 0.21) (Figure 5c ), but not in CD45RA/ RO þ and CD3 þ CD4 þ T cells (not shown). The recovery of B cells was not influenced by DLI with median of 28 (range, 0-278) versus 161 (range, 0-482) CD19 þ CD20 þ cells/ml on day þ 150 after transplantation. However, NK-cell reconstitution seems to be influenced by DLI with 389 (median, range, 60-1399) versus 317 (range, 180-2541) cells/ml on day þ 100 (P ¼ 0.58) (Figure 5d ).
Discussion
Graft composition and conditioning may be of great impact on the immune reconstitution after HHCT. We studied in detail the immune reconstitution after HHCT using RIC and CD3/CD19-depleted grafts. T-cell reconstitution after HCT in general follows two pathways: (1) peripheral expansion of cotransplanted cells from the donor.
14 (2) de novo generation of naïve T cells. 15 In the early phase, after transplantation, mainly the first pathway is apparent as the reconstitution of naïve T cells may be delayed up to 2 years after HCT. 16 Compared with Immune reconstitution after CD3/CD19 depleted HHCT B Federmann et al unmanipulated HLA-matched HCT, we observed a delayed reconstitution of T cells in our study population. This is most likely caused by the reduced peripheral expansion of donor T cells related to profound T-cell depletion. De novo generation of naïve T cells is delayed most likely because of an involuted thymus in our adult patient population. In children, a faster reconstitution of T cells is described after CD34 selection and CD3/CD19 depletion, respectively, 17 illustrating the positive impact of a functioning thymus. Evaluating T-cell subsets, we observed a quite parallel distribution between CD4 þ and CD8 þ T cells with a slow increase in the early phase and considerable increase from day þ 200. CD8 þ cytotoxic T cells have been described to regenerate faster, 18 whereas CD4 þ T-helper cells lack behind with subnormal values until 412 months after HHCT. 19 Analyzing the CD4 þ T cells, we observed a faster recovery of CD4/45RO þ memory T cells probably because of co-transplanted donor T-cell progenitors. This is consistent with the data of Shaffer et al. 20 using a nonmyeloablative conditioning in the haploidentical setting with a slow regeneration of T cells and predominance of memory T cells in the first 100 days. After CD34 selection CD4/ 45RA þ naïve T cells are reported to reconstitute after day þ 200. 21 Compared with published data on recovery of CD3 þ and CD3 þ /CD4 þ T cells after HHCT using CD34 selection and myeloablative conditioning, T-cell reconstitution after RIC and using CD3/CD19-depleted grafts seemed faster. However, the impact of conditioning and graft manipulation is hard to assess without direct comparisons. T-cell recovery in our cohort of patients was mainly driven by T cells of donor origin and not by persistent recipient T cells as described after other Figure 2 TCR repertoires of a patient with NHL before and after HHCT. At the time of HHCT almost normal TCR repertoire. On day þ 90, a skewed and restricted distribution. After day þ 200 stepwise completion and broadening of the repertoire. Overexpression of Vb-23 on day þ 90 (23.7% of CD3 þ cells/ml, standard value ¼ 0.85%) and Vb-8 (28.6% of CD3 þ cells/ml, standard value 4.68%) and Vb-14 (11.9% of CD3 þ cells/ml), standard value 3.49%) on day þ 325. These time points coincide with flairs of acute skin GVHD. Figure 3 Reconstitution of B cells. B-cell counts X100 cells/ml were present after a median of 150 days (range, 0-482). Median on day þ 40 (2 cells/ml), þ 100 (8 cells/ml), þ 150 (100 cells/ml), þ 250 (129 cells/ml) and þ 400 (275 cells/ml).
Immune reconstitution after CD3/CD19 depleted HHCT B Federmann et al nonmyeloablative RIC regimens as illustrated by complete donor chimerism in the T-cell compartment as early as 4 weeks after HCT. After CD34 selection median days to 4100 CD3 þ cells/ml were 140-154 days and to 4100 CD4 þ cells/ml 180-300 days. 21, 22 In our cohort, using CD3/CD19 depletion we observed 4200 CD3 þ cells/ml on day þ 100 and a median of 166 CD4 þ /CD3 þ cells on day þ 250. Seven patients received X5 Â 10 4 cells/kg in the graft. However, no distinct difference in immune reconstitution depending on the dose of T cells in the graft could be observed. Evaluating TCR-Vb repertoire we observed a decimated TCR repertoire already before HHCT probably because of the underlying disease and multiple preceding chemotherapies. In the first year after HHCT, the repertoire remained skewed without expression of most Vb-chains. As result of the profound graft T-cell depletion there are little T cells contained in the graft being able to contribute to an early normal distribution of TCR repertoire. These findings are comparable with results determined by TCR spectratyping after CD34 selection showing a modified TCR repertoire up to 3 years after allogeneic transplantation. 23 Before day þ 200, the T cells expressing the phenotype CD45RO þ , representing memory T cells derived from the donor 24 are found and stimulated to expand by the antigenic milieu in the host. 14 After day þ 200, naïve T cells with the phenotype CD45RA begin to increase and support the completion of a full TCR repertoire. These findings have been described previously by Eyrich et al. 21 after HHCT using CD34-selected grafts in a pediatric population. We observed that alterations in the TCR repertoire distribution as well as overexpresson of single Vb-chains at different time points are influenced by immunosuppression, GVHD and infectious complications. The skewed TCR repertoire may also have detrimental effects on clinical outcome.
In parallel to T-cell reconstitution, B-cell regeneration was also profoundly delayed. This is comparable to data in T-celldepleted HCT, with depression of B cells up to 12-18 months. 25 In this study, the delay in B-cell reconstitution is aggravated by the profound B-cell depletion of the graft. In addition, B-cell reconstitution might be negatively influenced by the lack of stimulation of B-cell maturation as a result of additional T-cell depletion. An additional negative impact may result from damage to the recipient bone marrow stroma by the preceding chemotherapy and radiation. 26 Immune reconstitution is influenced by graft composition and strategies to avoid GVHD in the haploidentical setting. Graft NK cells and fast NK-cell reconstitution might be of particular importance. The positive impact of NK cells on engraftment, graft-versus-tumor effect 27 and defense against infections has been shown. Cook et al. 28 demonstrated a significantly lower incidence of cytomegalovirus reactivation after transplantation from KIR-mismatched donors. There is also increasing evidence for the role of NK cells in the defense of fungal infections. 29 NK cells generally reconstitute early after HCT as described previously, comparing immune reconstitution after CD34 selection and unmanipulated grafts in the myeloablative setting. 30 After HHCT, using myeloablative conditioning, the peak of NK-cell reconstitution was reached after 3 months. 31 In contrast, we observed an overshooting and fast regeneration of NK cells with normal numbers already on day þ 20 after HHCT because of the high numbers of NK cells in the graft and a relative NK-cell lymphocytosis early after HHCT. Our results are comparable with data analyzing immune reconstitution after CD3/CD19 depletion in a pediatric cohort with fast recovery of NK cells reaching a normal levels already on day 14 32 and an analysis in HLA-identical HCT in adults comparing CD34-selected and CD3/CD19-depleted grafts after myeloablative conditioning. 33 Gentilini et al. 34 could even show a significantly faster and more sustained recovery of NK cells in a group of Figure 4 Reconstitution of NK cells. On day þ 20 after transplant the median NK cell count was 248 cells/ml (range, 1-886). Median on day þ 40 (231 cells/ml), þ 100 (332 cells/ml), þ 150 (329 cells/ml), þ 250 (314 cells/ml) and þ 400 (328 cells/ml). Immune reconstitution after CD3/CD19 depleted HHCT B Federmann et al patients after RIC-HCT with CD3/19-depleted grafts in comparison with patients with myeloablative HCT after CD34 selection and adoptive NK-cell infusion. In our study, NK cells represented more than 70% of lymphocytes in the early phase after HHCT as previously described. 35 This early and fast reconstitution of NK cells may explain the low rate of infectious complications observed early after transplantation in our cohort. In our study, expression of NKp44 was low during the first weeks after transplantation as expected in contrast with the higher expression of NKp30, 46 and NKG2D. The depletion of T cells in the graft and the resulting lower levels of interleukin-2 could further explain the lacking upregulation of NKp44 in the early phase after transplant. NKG2D decreased with time in contrast with the increased expression of natural cytotoxicity receptors. Amongst inhibitory receptors, we observed a high expression of CD94/NKG2A and CD161 in the early phase and a decrease of these receptors over time. An interesting observation was the low expression of the KIR receptors (KIR 2DL1, KIR2DL2/3 and KIR3DL1), which did not increase significantly for the first 90 days. This is consistent with the results of Nguyen et al. 36 in NK-cell-depleted grafts who provided evidence that a different expression of both KIRs and CD94/NKG2A is balanced during NK-cell-development. However, little is known about the influence of different graft-manipulation methods on KIR reconstitution. Some results implicate a difference in the development of NK cells between unmanipulated and T-celldepleted grafts. 37 We observed no influence of KIR-MM on OS in contrast to the data of the Perugia group who could demonstrate a positive impact of a KIR-MM on engraftment, relapse rate and survival. 38 This difference might be caused by the different graft manipulation methods and conditioning regimens used.
Application of DLI seems to have a positive impact on the regeneration of T-as well as NK-cells. NK-cell reconstitution was improved possibly by T-cell amplification of NK cells. 39 DLI might be a valuable strategy to enhance immune reconstitution after HHCT but can result in severe GVHD.
In summary, the results of our study demonstrate a distinct pattern of immune reconstitution after HHCT using CD3/CD19-depleted grafts and RIC. Engraftment is sustained and fast even without megadoses of CD34 þ stem cells. Owing to the large amount of NK cells contained in the graft, fast NK cell recovery Immune reconstitution after CD3/CD19 depleted HHCT B Federmann et al maintains the immune defense in the early phase after engraftment. T-and B-cells regenerate delayed but faster than reported after CD34 selection and high dose conditioning. Delayed T-and B-cell reconstitution, however, is still responsible for the occurrence of late infectious complications. Further prospective comparisons of the different graft manipulation methods for HHCT should allow more detailed analysis of the impact of graft composition on immune reconstitution.
